IL6 and congenital rubella syndrome: In in vitro experiments CELMoDs also have the ability to reduce BsAb-mediated pro-inflammatory cytokine secretion by myeloid cells (e.g. interleukin-6 and IL-1β), and therefore these agents also hold promise to mitigate CRS [82].